▟ Vinebot intrinsic value, daily

← back

DXCM Dexcom

healthcare · valued with opus medium conviction · deep-dived 2026-10-22

BUY
Intrinsic value$51.08
Price (at call)$80.26
Margin of safety -36.4%
vs market (rating basis) +16.3%

Durable CGM duopolist with a long Type 2 runway, but pricing pressure caps margins; fairly-to-richly priced.

The story

Dexcom is one of two scaled players in continuous glucose monitoring, sharing a duopoly with Abbott's Libre. Its moat comes from sensor accuracy, integration with insulin pumps, clinician loyalty and reimbursement relationships. It is a maturing growth company: the intensive-insulin market is well penetrated, and the remaining runway is Type 2 non-insulin users, international markets and over-the-counter products like Stelo. Growth in those segments comes with lower prices as more sales move to the pharmacy channel and Abbott competes on cost.

First-year growth of 13% is below the 17% five-year CAGR, reflecting a larger revenue base and pricing pressure in Type 2 and OTC. Margins move from 26% to a sustainable 27%, because scale gains are offset by price cuts, so I do not assume medtech-peak margins. Sales-to-capital of 1.6 (TTM is 1.25) reflects manufacturing scale-up already being in place. The 10-year horizon fits a durable duopoly with a long Type 2 runway, but not a 15-year franchise given Abbott's cost advantage.

Value drivers

Revenue growth (Y1)13.0%
Terminal growth3.5%
Forecast horizon10y
Target operating margin27.0%
Years to target margin5
Sales-to-capital1.60
Beta1.05
Failure probability2.0%
Cost of capital (WACC)9.7%
Terminal WACC9.5%

Valuation bridge

PV of explicit FCFF7.91B
PV of terminal value12.08B
Equity value19.28B
÷ shares → per share$51.08

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 5.62B 13.0% 26.2% 1.13B 403.75M 728.76M 664.42M
2 6.29B 11.9% 26.4% 1.28B 419.19M 857.67M 712.91M
3 6.97B 10.9% 26.6% 1.43B 427.79M 998.16M 756.45M
4 7.66B 9.8% 26.8% 1.58B 428.39M 1.15B 793.77M
5 8.33B 8.8% 27.0% 1.73B 420.00M 1.31B 823.76M
6 8.97B 7.7% 27.0% 1.86B 401.93M 1.46B 838.03M
7 9.57B 6.7% 27.0% 1.99B 373.79M 1.61B 843.75M
8 10.11B 5.6% 27.0% 2.10B 335.58M 1.76B 840.68M
9 10.57B 4.6% 27.0% 2.19B 287.74M 1.90B 828.85M
10 10.94B 3.5% 27.0% 2.27B 231.14M 2.04B 808.58M

Key risks

  • Abbott Libre's lower prices compress pricing, especially in the pharmacy and Type 2 non-insulin channels
  • Weaker reimbursement or slow coverage for Type 2 non-insulin patients limits the volume runway
  • Quality and recall problems or FDA warning letters that hurt sensor reliability and trust
  • GLP-1 drugs reduce disease progression and slow growth in insulin-using patients

Catalysts

  • Broader reimbursement for Type 2 non-insulin CGM and scaling of the Stelo OTC product
  • Next-generation sensor launches (longer wear, smaller form factor) that improve unit economics and gross margin

History

DatePriceIntrinsicMoSRating
2026-10-22$80.26 $51.08 -36.4% BUY
2026-09-02$90.14 $34.07 -62.2% HOLD
2026-07-13$74.96 $44.25 -41.0% BUY
2026-06-23$68.92 $47.60 -30.9% STRONG BUY